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PPARα and HNF4α are nuclear receptors that control gene transcription by direct binding to speciﬁc nucleotide sequences. Using
transgenic mice deﬁcient for either PPARα or HNF4α, we show that the expression of the peroxisomal 3-keto-acyl-CoA thiolase
B (Thb) is under the dependence of these two transcription factors. Transactivation and gel shift experiments identiﬁed a novel
PPARresponseelementwithinintron3oftheThbgene,bywhichPPARαbutnotHNF4αtransactivates.Intriguingly,wefoundthat
HNF4αenhancedPPARα/RXRαtransactivationfromTBPPRE3inaDNA-bindingindependentmanner.Coimmunoprecipitation
assays supported the hypothesis that HNF4α was physically interacting with RXRα. RT-PCR performed with RNA from liver-
speciﬁc HNF4α-null mice conﬁrmed the involvement of HNF4α in the PPARα-regulated induction of Thb by Wy14,643. Overall,
we conclude that HNF4α enhances the PPARα-mediated activation of Thb gene expression in part through interaction with the
obligate PPARα partner, RXRα.
1.Introduction
Peroxisomes are essential organelles for various metabolic
pathways including β-oxidation of very long-chain fatty
acids (VLCFAs), prostaglandins, and leukotrienes as well as
detoxiﬁcation of xenobiotics and reactive oxygen species.
Besides catabolic events, biosynthesis of cholesterol, bile
acids, dolichol, and ether lipids (plasmalogens) also occurs
within the peroxisomal matrix. While both mitochondria
and peroxisomes are the main sites for cellular fatty
acid degradation by oxidation, β-oxidations by these two
organelles diﬀer substantially in the substrate speciﬁcity.
Whereas mitochondria mainly oxidize short, medium, and
most long-chain fatty acids, peroxisomes preferentially oxi-
dize very long straight-chain fatty acids (VLCFAs) (C > 20)
and branched-chain fatty acids (BCFAs) [1].
Peroxisomal β-oxidation of VLCFAs can be divided in
four main steps: dehydrogenation, hydration, oxidation, and
thiolytic cleavage. While diﬀerent enzymes are involved
in the diﬀerent biochemical reactions, thiolytic cleavage
is accomplished by three enzymes in rodents, namely, 3-
ketoacyl-CoA thiolase A (ThA), 3-ketoacyl-CoA thiolase
B (ThB, EC:2.3.1.16), and Sterol Carrier Protein X/Sterol
Carrier Protein 2 thiolase (SCPx/SCP2).
In rodents, the Tha and Thb genes encode two distinct
proteins that diﬀer by 9 amino acids and display similar2 PPAR Research
substrate speciﬁcity in vitro [2]. However, the Tha and Thb
genes do not exhibit overlapping expression patterns [3].
While Tha is ubiquitously expressed, Thb is mainly present
in liver and kidney [4]. The diﬀerence in tissue distribution
suggests that ThA and ThB may have diﬀerent biological
activities. While ThB is assumed to be important for VLCFA
metabolism,theexactfunctionofthisproteininvivoremains
to be established. Although Thb−/− animals are phenotypi-
callyindistinguishable from wild-type littermatesundernor-
mal conditions, feeding the potent peroxisome proliferator
activated receptor alpha (PPARα, NR1C1) agonist Wy14,643
(Wy) led to enrichment of the n-7 and n-9 medium chain
unsaturated fatty acids (MUFAs) in the liver [5].
PPARs are ligand-activated nuclear hormone receptors
involved in the regulation of numerous processes, including
glucose, amino acid and lipid metabolism, inﬂammation
and wound healing [6–8]. The three PPAR isotypes (α,
β/δ,a n dγ) each regulate a distinct set of target genes by
binding to DNA sequences consisting of two repeats of the
consensus sequence AGGTCA separated by one nucleotide
(Direct Repeat 1, DR1). DR1 sites speciﬁcally bound by
PPARs and their dimerization partner retinoid x receptor
(RXR) are also known as peroxisome proliferator response
elements (PPREs) and are present either in the promoter
region and/or intronic sequences of genes [9, 10]. The role
of the nuclear receptor PPARα in hepatic fatty acid oxidation
has been well documented [11]. PPARα serves as a nuclear
receptor for fatty acids and is activated by the ﬁbrate class of
drugs, which are used in the treatment of dyslipidemia (low
plasma HDL/high triglycerides). Transcriptional control of
ThaandThbbyPPARsintheliverhasbeenshown previously
and involves a functional PPRE (TB PPRE2) in intron 3 of
the Thb gene [12].
In addition to PPARα, the liver-enriched transcription
factor hepatocyte nuclear factor-4α (HNF4α,N R 2 A 1 )a l s o
plays a pivotal role in glucose, amino acid, and lipid
metabolism. Because HNF4α is also known to recognize
DR1-bindingsites, PPARα and HNF4αshare common target
genes, as previously shown for glycogen synthase-2, acyl-Coa
thioesterase I, and ornithine transcarbamylase [7, 13, 14].
Another putative candidate for dual PPARα and HNF4α
regulation is Thb. A DR1 sequence (TB PPRE1) found in the
promoter of Thb was shown to be bound by both PPARα
and HNF4α in vitro [15]. To conﬁrm the in vivo relevance
of this ﬁnding, the present study assesses the regulation of
Thb by the nuclear receptors PPARα and HNF4α in vivo,
using PPARα−/− and hepatic HNF4α-null mice, respectively
[16–18]. These in vivo models in combination with cell
culturetoolsprovideevidencefortheinvolvementofHNF4α
in Wy induction of Thb by interacting with the PPARα
dimerization partner retinoid x receptor alpha (RXRα)a ta
nonconventional PPRE located within intron 3 of the Thb
gene.
2.Materialsand Methods
2.1. Animal Experiments. Nine-week-old C57BL/6J PPARα-
null male mice and age-matched WT mice were used.
Mice were kept in cages at 22◦C, with equal periods of
darkness and light and had free access to water and food
containing 4.3% (w/v) lipids (U.A.R.A-03, Epinay sur Orge,
France). For the pharmacological intervention, wild-type
(WT) and PPARα- n u l lm i c ew e r ef e db yg a v a g ef o r8d a y s
with Wy (30mgkg−1·day−1 from Sigma). Control animals
received the vehicle alone (3% arabic gum). Six-week-old
liver-speciﬁcally HNF4α-disrupted(HNF4α
￿L)andcontrol
(HNF4α F/F) mice were fed a grain diet with or without
(0.1% w/w) Wy for 5 days. Animals were sacriﬁced by cervi-
cal dislocation and tissues were rapidly snap-frozen in liquid
nitrogen before storing at −80◦C. Ethical considerations: in
vivo studies were conducted under EU guidelines for the use
and care of laboratory animals and were approved by an
independent ethics committee.
2.2. Cell Culture. COS-7 cells were grown as previously
described [12, 15]. Brieﬂy, COS-7 cells, mouse hepatoma
Hepa 1.6 and human HeLa cells were routinely grown
in Dulbecco’s Modiﬁed Eagles Medium (DMEM) medium
supplementedwith10% FCSand fetal calfserum(FCS)were
from PAN Biotech GmbH. Rat hepatoma H4IIEC3cells were
grown in DMEM/HAM’S F-12 (1/1) medium supplemented
with 5% FCS. All cells were grown in absence of antibiotics
in the culture medium. Regular testing for mycoplasma
contamination was performed with a PCR-based test.
2.3.IsolationofTotalRNAandNorthernBlottingExperiments.
Total RNAwas extracted from 50 mg from liver using TRizol
reagent according to the method speciﬁed by the supplier
(Invitrogen). Total RNA (15μg) was resolved on 1% agarose
gels containing 6% (v/v) formaldehyde and transferred
to Hybond-N membranes (Amersham Biosciences). Filters
were hybridized overnight with 32P-labeled cDNA probes.
Thb and 36B4 probes were previously described [3]. The
Acox-I DNA probe was obtained by RT-PCR from mouse
liver total RNA and veriﬁed by sequencing.
2.4. Isolation of Total RNA, Reverse-Transcription and Con-
ventional PCR. Hnf4loxP/loxPAlfp.cre mutant mouse embryos
[19]a n dHnf4loxP/loxPAlfp.cre adult mice [17]w e r ep r e v i o u s l y
reported elsewhere. Total RNAfrom 18.5-d.p.c and adult liv-
ers were extracted using Qiagen’s RNeasy mini kit following
the manufacturer’s protocol. Contaminating genomic DNA
wasremovedusing 10uRNase-free-DNAse I/μgRN A.cDN A
was synthesized using MMLV-RT (Invitrogen) with dNTP
(0.5mM) and random hexamer primers (5μM). These DNA
provided template using speciﬁc primers at the annealing
temperature of 57◦C in the presence of dNTP (0.1mM),
primers (0.5μM), and Taq DNA polymerase (Roche).
2.5. Reverse Transcription and Real-Time Quantitative PCR
(RT-qPCR). Total RNA from Hepa 1.6 cells was extracted
and puriﬁed using Qiagen RNeasy columns (Qiagen). One
μg of total RNA was used for reverse transcription with
iScript Reverse Transcriptase (BioRad). PCR reactions were
performed using the qPCR MasterMix Plus for SYBR
Green I with ﬂuorescein (Eurogentec). All PCR reactionsPPAR Research 3
were performed with MultiGuard Barrier Tips (Sorenson
BioScience, Inc.) and an iCycler PCR machine (Bio-Rad
Laboratories). Primers were designated to generate a PCR
ampliﬁcation product of 100–200bp and were selected
according to indication provided by the Primer 3 software
(http://frodo.wi.mit.edu/primer3/). Sequences are available
from S. Mandard on request. Speciﬁcity of the ampliﬁcation
was veriﬁed by melting curve analysis and evaluation of
eﬃciency of PCR ampliﬁcation. The “delta-delta Ct” quan-
tiﬁcation method was used and expression was related to the
control gene 36B4, which did not change under any of the
experimental conditions studied.
2.6. Transactivation Assays. COS-7 and HeLa cells were
transfected with Exgen 500 (Euromedex) following manu-
facturer’s protocol. 5 × 104 cells/well were seeded in a 24-
wells plate. Cells were transfected with a mixture of 1μg
of plasmid DNA containing 30ng of the reporter vector
pCMV β-galactosidase (Clontech) together with equivalent
molar amount of Luciferase (Luc) vectors (about 250
ng). Diﬀerent amounts of expression vectors encoding for
diﬀerent nuclear receptors such as pSG5-mPPARα,p S G 5 -
mRXRα,a n dp C D N A 3 - h H N F 4 α were used. Corresponding
empty vectors were used for control experiments. 4 h
post transfection, the culture medium was replaced by
1ml of complete medium with or without 10−5 MW y
(Alexis Biochemical). Luc and β-galactosidase activities
were measured 48 h post transfection using the Promega
Luc kit (Promega) and a standard assay. Chlorophenol
red β-D-galactopyranoside was used as a substrate for
β-galactosidase. For each condition, transfection assays
were repeated four times. Reporter pGluc constructs was
composed of a Luc expression vector containing the β-
globin promoter upstream of the Luc coding sequence.
TB PPRE3-pGluc was created by inserting synthetic double
strand oligonucleotides between HindIII and BamHI sites
of the pGluc vector (top strand HindIII +935
AGCT TGACCTGAC-
CTCTGCTCGATAACCTTTTCCCTACTT+970,lowerstrand
BamHI+970
GATC CTCTAAGTAGGGAAAAGGTTATCGGCAGAG-
GTCAGGTCA+970; ACOX-I PPRE, and MFP1-PPRE have
been described previously [20, 21]. Hepa 1.6 cells (8 × 105
in a 12-well plate) were transfected with LipofectamineTM
2000 (Invitrogen), H4IIEC3 cells (1 × 106 in a 6-well
plate)with FuGeneHD (Roche)according tomanufacturer’s
instructions.
2.7. Expression and Reporter Vectors. The expression vectors
pSG5-mPPARα and pSG5-mRXRα were a kind gift of Dr.
Stephen Green (UK). The expression vectors encoding the
mutated form of HNF4α (DN HNF4) was provided by
Dr Todd Leﬀ (Wayne State University School of Medicine,
Detroit, Michigan, USA). DN HNF4 is a selective dominant
negative mutant that forms defective heterodimers with
WT HNF4α preventing DNA binding and transcriptional
activation by HNF4α.D NH N F 4i su n a b l et ob i n dD N Ao n
its own [22]. The mammalian expression vector encoding
D126Y HNF4α2 was a kind gift of Dr. Bernard Laine
(INSERM U459, Lille, France) [23].
2.8. Transient Transfections of Hepa 1.6 Cells with AMAXA
Technology. Hepa 1.6 cells were routinely grown in DMEM
medium supplemented with 10% Fetal Calf Serum. Hepa 1.6
cells (×107) were resuspended in 100μl of the transfection
solution provided with the transfection kit (Nucleofector
kit V). Per transfection, 5μg of DNA were added to the
cell suspension. The cell-DNA mix was transferred into the
Amaxa transfection cuvette using the Amaxa minipipette.
The cuvette was next placed into the Nucleofector and the
program “T-028 High Eﬃciency” was selected. 500μlo f
warm media were added to the cuvette and transfected cells
were transferred tothedish (25cm2)withpr ewarmedmedia.
24 h post transfection, culture medium was changed. Total
RNA was extracted 48 h post transfection.
2.9. Gel shift and Supershift Assay. Nuclear extracts were
prepared from transfected COS-7 cells (2 × 106 cells per
100-mm dish, with 8μg of appropriate expression plasmid).
Nuclei and nuclear extracts were prepared as previously
indicated [24]. Protein concentrations were determined by
the Bradford assay (BioRad). Oligonucleotides were end
labelled with dCTP by using the Klenow fragment of
DNA polymerase I. Nuclear extracts (0.5μgf o rh H N F 4 α-
enriched extracts) were incubated for 1h on ice in 20μl
of the buﬀer (10mM Hepes pH 7.9; 120mM NaCl, 1mM
EDTA, 1mM DTT, 7% (v/v) glycerol, 0.5mM PMSF, 2μg
each of leupeptin, aprotinin, pepstatin), 1μgo fd o u b l e -
strandedpoly(dIdC),and35fmolofradiolabelledratPPRE3
oligonucleotide. Alternatively, a 1 to 100 fold molar excess
of competitor oligonucleotides was added. The HNF4α anti-
body used for supershift was from Santa Cruz Biotechnology
Inc. (HNF4α sc-8987x) and was added with the nuclear
extract 30 minutes before adding the probe. Nucleoprotein
complexes were resolved on a 6% (w/v) polyacrylamide gel
in 1x TBE.
2.10.Coimmunoprecipitation(CoIP)Assays. ForCoIPassays,
nuclear extracts were adjusted to 25mM HEPES (pH 7.9),
200mM KCl, 1mM EDTA, 0.5% NP-40, and 10% glycerol
and incubated with 2μgo fa n t i b o d ya t4 ◦C for 12h. 50μlo f
protein G-Sepharose beads were washed twice with the same
buﬀer before being incubated for 2h with the upper mixture
on a rotator. After a centrifugation step, pelleted beads
were washed four times with the afore-mentioned buﬀer.
After unbound proteins were washed away, bead pellets
were ﬁnally resuspended in reducing loading buﬀer [25]a n d
samples were boiled at 95–100◦Cf o r3 – 5m i n u t e sb e f o r e
beingsubjectedtoSDS-PAGE.TheHNF4α(sc-6556),PPARα
(sc-9000x), RXRα (sc-774), as well as the secondary (donkey
anti-goat, sc-2020) antibodies used were all purchased from
Santa-Cruz Biotechnology Inc.
2.11.DNAAﬃnityPrecipitationAssay(DAPA). DNAAﬃnity
Precipitation Assay (DAPA) was performed as previously
described [26]. Proteins were eluted in 15μl of SDS-
PAGE loading buﬀer by heating for 5min at 95◦C. The
streptavidin magnesphere paramagnetic beads were from
Promega (Z5481). Similar antibodies as those used for4 PPAR Research
coimmunoprecipitation assays were used except for the
secondary antibody (goat antirabbit, sc-2004, Santa-Cruz
Biotechnology Inc.).
2.12. Immunoblotting. Immunoblotting of the two perox-
isomal 3-ketoacyl-CoA thiolases (PTL) was performed as
previously described [27]. The rabbit polyclonal antibodies
directed against both thiolase A and B proteins (PTL) was
a gift from Dr. T. Hashimoto and Dr. N. Usuda (Shinshu
University School of Medcine, Japan) and has been previ-
ously described [27]. Signals were detected with ECL-plus
(Amersham Biosciences) according to the manufacturer’s
instructions.
2.13. Statistical Analyses. Unless indicated, the one-way
ANOVA test was used to identify statistically signiﬁcant
diﬀerences. The cut oﬀ for statistical signiﬁcance was set at
a P-value of .05 or below.
3.Results
3.1. Thb mRNA Levels Are Robustly Induced by the PPARα
Agonist Wy in Liver. Using a cDNA probe recognizing both
Tha and Thb genes, it was previously shown that thiolase
(A + B) mRNA levels were induced by PPARα agonists in
aP P A R α-dependent manner [18]. To evaluate whether Thb
only was sensitive to PPARα agonists, northern blot analysis
was performed using a speciﬁc nucleotide probe and hepatic
RNA from WT and PPARα-null mice treated or not with
Wy14,643 (Wy), a potent and speciﬁc agonist of PPARα
(Figure 1(a)).
Underbasal conditions, Thb mRNAlevelswere similar in
wild-type (WT) and PPARα-deﬁcient mice. The expression
of the PPARα target gene Acox-I and of Thb were induced
in a PPARα-dependent manner (Figure 1(a)). Of note, the
augmentation of Thb mRNA levels upon Wy treatment was
translated into higher peroxisomal 3-ketoacyl-CoA thiolases
protein content (Figure 1(a)).
To further investigate whether the in vitro expression
of Thb is also controlled by PPARα in other species, rat
hepatoma H4IIEC3 cells were treated with Wy. Using RT-
qPCR, it was shown that Thb mRNA levels were robustly
induced by activated PPARα (Figure 1(b)). Given the dra-
matic activation of Thb expression by Wy in H4IIEC3 cells,
more than a single PPRE in the rat Thb gene sequence may
control its expression. Comparison with other established
PPARα target genes such as Acox-I and Mfp-1 indicated that
the gene expression proﬁle of Thb was indeed closer to that
of Mfp-1 (one of the most responsive gene to PPARα due to
the presence of an atypical and composite PPRE in its gene
sequence) than Acox-I (Figure 1(b))[ 28, 29].
3.2. Identiﬁcation of TB PPRE3 as a Novel Response Element
for PPARα. To ﬁnd out for more functional DR1 PPREs, a
comparative in silico analysis of the mouse and the rat Thb
genes sequences from position −5600bp upstream of the
transcription start site to position +13000bp downstream
was performed with Nubiscan V2.0 software [30]. It revealed
thepresenceofseveralconservedstretches ofDNAsequences
that harboured some previously characterized PPREs as
well as a novel PPRE that we named TB PPRE3 [12,
15]( Figure 1(c)). Gel mobility shift assays were used to
test whether TB PPRE3 was bound in vitro by translated
PPARα/RXRα proteins. In agreement with data previously
reported by others, we found a retarded PPARα/RXRα
complex on MFP-1 PPRE but also on TB PPRE3, further
implying direct regulation of Thb by PPARα through TB
PPRE3 [28]( Figure 1(d)).
To verify whether PPARα can transactivate the Thb gene
throughTBPPRE3,transactivation assays wereperformed in
COS-7 cells with a reporter vector containing a single copy
of TB PPRE3. Luc activity of the reporter vector containing
TB PPRE3 responded signiﬁcantly to PPARα overexpression
in the absence of exogenous agonist (Figure 1(e)). Since
the apparent large responsiveness of PPARα in absence of
exogenous ligand may reﬂect the high constitutive activ-
ity mediated by the ligand-independent AF1 domain, we
examined the behaviour of N-terminally deleted (ΔAF1)
PPARα construct that lacksthe AF1intransactivation assays.
It was found that ΔAF1 PPARα behaved similarly to WT
PPARα, suggesting the presence of natural PPARα agonists
in the culture medium (data not shown). As expected, Luc
activity was signiﬁcantly enhanced after Wy treatment. It
is important to note that the MFP-1 PPRE is composed
of two DR1 elements separated by two base pairs, thereby
forming an internal DR2 element (Figure 1(c))[ 28, 29].
With the exception of a single-base pair separating two
putative DR1, the overall structure of TB PPRE3 was quite
similar to that of MFP-1 PPRE. Yet, it is also worth noting
that the nucleotide sequence composing the four diﬀerent
half-sites of TBPPRE3signiﬁcantly diﬀersfromthatofMFP-
1 PPRE. Of interest and compared to ACOX-IPPRE, the fold
induction for TB PPRE3 and MFP-1 PPRE were quitesimilar
as a probable consequence of their unusual and composite
structure (Figures 1(c) and 1(e)). Overall, TB PPRE3 is a
potent response element for PPARα and is likely critical for
PPARα-dependent activation of Thb gene transcription.
3.3. The Nuclear Orphan Receptor HNF4α Controls Thb
Gene Expression in Liver and in Hepatoma Hepa 1.6 Cells.
The liver Hepatocyte Nuclear Factor-4α (HNF4α,N R 2 A 1 )
plays an important role in the transcriptional regulation of
genes involved in diﬀerent metabolic pathways, including
fatty acid, amino acid, glucose, and cholesterol metabolism.
Although limited, there is some overlap in the identity of
some of the HNF4α and PPARα regulated genes [6, 31, 32].
In view of this, HNF4α might be hypothesized to directly
control Thb gene expression in liver. Because the complete
deletion of Hnf4α is lethal in mice, we sought to check
whether deletion of Hnf4α had any impact on liver Tha and
Thb basal expression using samples from Hnf4α−/− 18.5 days
old embryos (Figure 2(a))[ 16, 19].
While mRNA levels of Tha were not aﬀected, Thb
mRNA levels were markedly decreased in liver of
Hnf4loxP/loxP Alfp.cre embryos supporting a critical role
for HNF4α in regulating the basal expression of Thb duringPPAR Research 5
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Figure 1: Wy induces hepatic Thb gene expression in a PPARα-dependent manner through a novel PPRE. (a) Northern blot was performed
with liver RNA from wild-type (n = 3) and PPARα−/− mice (n = 3) fed Wy (30mgkg−1·day−1) for 8 days. Autoradiographs were quantiﬁed
and average fold changes indicated below the diﬀerent blots. The signal for WT mice NOT fed Wy was arbitrarily set to 1. 36B4 mRNA
levels were evaluated and used as internal control of loading. Western blot experiment was conducted with liver protein samples of the same
animalsusing anantibody that recognizes the two peroxisomal 3-ketoacyl-CoA thiolases (PTL) identiﬁed in rodents [35]. (b) Rat hepatoma
H4IIEC3 cells were treated with Wy (10 or 50μM, as indicated) for 48 h. Expression of Thiolase b (Thb), AcylCoA oxidase-1 (Acox-1),
and Multifunctional protein-1 (Mfp1) was determined by quantitative RT-PCR analysis.Values are mean of three independent experiments
±SEM. Wy: Wy14,643. (c) The Thb gene contains a composite PPRE in intron 3. The nucleotide sequence of the diﬀerent PPREs (TB
PPRE3, ACOX-I PPRE, and MFP-1 PPRE) used in this study is shown. The nucleotide positions are given taking as +1 the transcription
initiation site. The diﬀerent arrows indicate half-site of a Direct Repeat (DR). (d) A double-strand oligonucleotide containing TB PPRE3 or
MFP1-PPRE was incubated with increasing amounts of in vitro translated PPARα and RXRα proteins. Binding complexes were separated by
electrophoresis. (e) Transactivation assays were performed in COS-7 cells with a Luc reporter vector containing either a single copy of TB
PPRE3 or a copy of ACOX-I PPRE or MFP-1 PPRE. These constructs were transfected together with an expression vector for mouse PPARα
(pSG5 mPPARα)i np r e s e n c eo ra b s e n c eo fW y( 1 0μM). DMSO was used as vehicle. Values are mean of four independent experiments
±SEM. ∗∗∗Eﬀect statistically signiﬁcant compared to control (no PPARα transfected, DMSO) with
∗∗∗P <. 001 with one-way Anova test.
Errors bars represent SEM.6 PPAR Research
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Figure 2: HNF4α is a master gene for the hepatic expression of Thb. (a) Expression of hepatic Thb in HNF4α null (Hnf4
loxP/loxPAlfp.cre;
loxP/loxP) and control (Hnf4loxP/+Alfp.cre; loxP/+) mouse embryos was determined by semiquantitative RT-PCR analysis(n = 3p e rg r o u p ) .
Hprt mRNA livers were evaluated and used as internal standard of loading. Tha:t h i o l a s eA ;Thb:t h i o l a s eB ;Hnf4α: Hepatocyte Nuclear
Factor-4 alpha; Hprt: Hypoxanthine-guanine PhosphoRibosyl Transferase. (b) Mouse Hepa 1.6 hepatoma cells were transfected with
expression vectors for WT HNF4α or dominant negative form of HNF4α (DN HNF4). Expression of Thb, Tha, and apolipoprotein AII
(ApoA-II) was determined by quantitative RT-PCR. Crude results were standardized against 36B4 mRNA levels. Levels of gene expression
in Hepa 1.6 cells transfected with empty pcDNA3.1 vector serve as reference point and are given the arbitrary value of 1.0. Values are
mean of three independent experiments ±SEM. Apolipoprotein AII (ApoAII) gene expression was used as a positive control of experiment.
Signiﬁcantly diﬀerent compared to control (transfection with empty pcDNA3.1 vector) with
∗P <. 05 and
∗∗P <. 01 by one-way ANOVA
test. n.s.: no statistically diﬀerent compared to control.
development of hepatocytes (Figure 2(a)). It may also
be hypothesized that the decrease in Thb mRNA levels
observed in liver of the Hnf4loxP/loxPAlfp.cre embryos could
be the consequence of metabolic perturbations due to
the lack of HNF4α. To exclude this possibility, and since
we have no way to pharmacologically activate HNF4α in
vivo,w es t u d i e dt h ee x p r e s s i o no fThb in mouse Hepa 1.6
hepatocytes that were eﬃciently transfected (using ThePPAR Research 7
Amaxa Nucleofector technology) with either a WT form
or with the potent dominant-negative form of HNF4α
(DN HNF4) previously characterized [22]. DN HNF4
is a selective dominant negative mutant that contains a
defective DNA-binding domain. Hence, DN HNF4 forms
defective heterodimers with WT HNF4α thereby preventing
DNA binding and subsequent transcriptional activation by
HNF4α. Compared to COS-7 and HeLa cells, mouse Hepa
1.6 and rat H4IIEC3 hepatoma cells express large amount
of endogenous WT HNF4α (data not shown). Ectopic
expression of WT HNF4α in Hepa 1.6 hepatocytes had a
minor impact on Thb and Tha mRNA levels, as shown by
RT-qPCR (Figure 2(b)). A similar picture was also observed
for ApoAII, a previously characterized HNF4α target gene
[33]. However, forced expression of DN HNF4 decreased
Thbas well as ApoAII mRNAlevelsby 50%while Tha mRNA
remained unchanged, conﬁrming that HNF4α controls the
basal Thb gene expression. Together, our data indicate that
HNF4α is a novel regulator of Thb expression in cell lines of
hepatic origin.
3.4.HNF4αBinds toTB PPRE3. Giventhat HNF4αis critical
for the basal expression of Thb and that HNF4α recognizes
DR1 sequences, we examined whether HNF4α may bind to
TB PPRE3 [34]. Using TB PPRE3 as a probe together with
HNF4α-enriched nuclear extracts from HNF4α-transfected
COS-7 cells, we performed electrophoresis mobility shift
assays. A complex was seen when enriched HNF4α nuclear
extracts were used (Figure 3(a),l a n e2 ) .
This complex mainly contained HNF4α since it was
absent in untransfected COS-7 cells (lane 1) and it dis-
appeared upon the addition of an excess amount of the
unlabelled ACOX-I PPRE consensus oligonucleotide (lane
3 to lane 5), previously shown to be eﬃciently bound by
HNF4α. An excess amount of cold nonspeciﬁc Sp1 binding
site oligonucleotide did not decrease HNF4α binding to
PPRE3 (lane 6 to lane 8). Addition of HNF4α speciﬁc
antibody with the nuclear HNF4α enriched extracts super-
shifted the complex (Figure 3(b), lane 2). Together, our data
demonstrate the in vitro binding of HNF4α to TB PPRE3.
To assess whether TB PPRE3 is able to mediate HNF4α-
dependent transactivation, transient transfections were per-
formed with HNF4αand reporter vectors containing a single
copy of TB PPRE3 sequence. While signiﬁcant, HNF4α only
modestly modulated transcription via TB PPRE3 in COS-7
cells (Figure 3(c)) indicating that TB PPRE3 behaves poorly
as a HNF4α response element in classical transactivation
assays and suggesting that binding of HNF4α to TB PPRE3
is not necessarily translated into a massive transcriptional
activation. Additional transactivation assays performed with
5.65kb of the mouse Thb gene promoter sequence also
failed to demonstrate HNF4α-dependent promoter acti-
vation (data not shown). We concluded that the critical
response element(s) for HNF4α, if any, was likely located
elsewhere.
In light of this consideration, Bolotin et al. recently
reported on an integrated approach for the identiﬁcation
of human HNF4α target genes using protein binding
microarrays [35]. This strategy allowed the discovery of a
DNA sequence bound by HNF4α in the human version
of the peroxisomal 3-ketoacylCoA thiolase (also known
as 3-acetyl-CoA acetyltransferase-1, ACAA1). Because we
found a similar sequence in intron 5 (DR1int5) of the
mouse Thb gene, transactivation assays were performed
in COS-7 cells using a copy of DR1int5 cloned in front
of the luciferase reporter gene (Figure 3(d)). Transfection
with HNF4α enhanced reporter activity to about 3-fold,
suggesting that DR1int5 is partly involved in the regulation
of Thb by HNF4α.
3.5. HNF4α Enhances the PPARα-Mediated Activation of
Transcription from TB PPRE3. It is widely documented that
HNF4α and PPARα share some similar binding motifs
leading to competition between these two receptors. To
check whether the same holds true for TB PPRE3, both
receptors were cotransfected either in nonhepatic (COS-7,
HeLa) or hepatic cells (Hepa 1.6, H4IIEC3). Whatever the
cell line used, PPARα/RXRα heterodimer increased reporter
activity which was even further enhanced by cotransfection
of HNF4α (Figures 4(a) and 4(b)).
As previously reported by others, cotransfection
with HNF4α strongly suppressed PPARα/RXRα increased
reporteractivity whenLucactivity wasdrivenbytheACOX-I
PPRE motif (Figure 4(c)). Hence, we concludedthat HNF4α
promotes transactivation mediated by PPARα/RXRα from
TB PPRE3 through a molecular mechanism that remains to
be determined.
3.6. Binding of HNF4α to TB PPRE3 is Dispensable for
the Cooperation with PPARα. Inasmuch HNF4α positively
inﬂuenced the ability of PPARα to transactivate the TB
PPRE3, it may suggest a possible cooperation between both
receptors. To test whether this synergistic eﬀect by HNF4α
dependsonits capacityto bind to TB PPRE3, transactivation
assays were conducted in COS-7 cells using two diﬀerent
mutant forms of HNF4α for which DNA binding is either
limited (−75%, as a consequence of a point mutation within
itsDNAbindingdomain,D126YHNF4α2)orabolished(DN
HNF4) while their stability remains unaﬀected (Figure 5(a))
[22, 23].
While the transactivation potential of D126Y HNF4α2
is reduced, dimerization of the receptor was not reported
to be aﬀected. Similar to WT HNF4α, over-expression of
either D126Y HNF4α2 or DN HNF4 failed to transactivate
thenative TBPPRE3 (Figure 5(b)).Noteworthy,bothD126Y
HNF4α2 and DN HNF4 potentiated further than WT
HNF4α the transactivation by PPARα from TB PPRE3.
Together, we conclude that the cooperation between HNF4α
and PPARα was not dependent on the physical binding of
HNF4α to TB PPRE3.
To ﬁnally check whether the cooperative eﬀect between
PPARα and HNF4α depends on the DNA nucleotide
sequence itself, we performed transactivation assays using
the DR-1 PPRE of the Acyl-CoA Oxidase I (ACOX-I PPRE)
(Figure 5(c)). In contrast to TB PPRE3, overexpression of8 PPAR Research
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Figure 5: Binding of HNF4α to TB PPRE3 is dispensable for the cooperation with PPARα/RXRα. (a) Positions of mutations used in this
study. A scheme of HNF4α structure with the various domains is given: DBD, DNA-binding domain; LBD, ligand-binding domain; AF2,
activation function 2 module. (b) Transactivation assays were performed in COS-7 cells with a Luc reporter vector containing isolated
TB PPRE3 (b) or mouse ACOX-I PPRE (c). These constructs were cotransfected with expression vectors for both mouse PPARα (pSG5-
mPPARα)a n dR X R α (pSG5-mRXRα) together with an expression vector encoding either wild-type HNF4α (HNF4α2 WT), a ﬁrst (D126Y
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Values are mean of three independent experiments ±SEM. DMSO was used as vehicle. Signiﬁcantly diﬀerent between PPARα/RXRα and
PPARα/RXRα +H N F 4 α with
∗∗P <. 01 and
∗∗∗P <. 001 by one-way ANOVA test.
WT HNF4α potently decreased Luc activity by the acti-
vated PPARα/RXRα heterodimer. Transfecting expression
vectors encoding the two mutant forms of HNF4α led to a
comparatively moderate decrease in Luc activity. Therefore,
we hypothesized that the competition between PPARα and
HNF4α was reduced. The two mutants were unable to
drive Luc activity to a level higher than the PPARα/RXRα
heterodimer alone, conﬁrming the lack of cooperation with
HNF4α. Overall, our data suggest that the cooperation
between HNF4α and PPARα receptors may depend on bothPPAR Research 11
the structure and the nucleotide sequence of the DNA
response element.
3.7. HNF4α Does Not Favour the Binding of PPARα/RXRα to
TB PPRE3. The molecular mechanisms by which the stimu-
latoryeﬀectofHNF4αonPPARα/RXRα-mediatedactivation
of transcription via TB PPRE3 does not require the binding
of HNF4α to DNA but at the present time, this mechanism
remains unclear. We, therefore, questioned whether HNF4α
couldfacilitate the binding of the PPARα/RXRαheterodimer
to TB PPRE3, via a possible protein-protein interaction.
We used DNA Aﬃnity Precipitation Assay (DAPA) to assess
complex formation on TB PPRE3 with PPARα,R X R α and
HNF4αproteins coming from nuclear extracts of transfected
COS-7 cells (Figure 6(a)).
Ectopic expression of PPARα in COS-7 cells led to
the production of the PPARα protein (Figure 6(b), lane 1)
and overexpressed HNF4α was not detected by the PPARα
antibody (Figure 6(b), lane 4). Consistent with our previous
ﬁndings (Figure 1(d)), we conﬁrmed that PPARα was bound
toTB PPRE3(Figure 6(b),lane 2).WhenPPARα,R X R α,and
HNF4α proteins were incubated altogether with TB PPRE3,
the signal was similar indicating that HNF4α does not favor
the binding of PPARα/RXRα to TB PPRE3.
We, therefore, concluded that the enhancement of the
PPARα/RXRα mediated-activation of transcription from TB
PPRE3 by HNF4α was likely not due to DNA binding
stabilization of the PPARα/RXRα heterodimer.
To go a step further, immunorevelation of the com-
plexes was also performed with a HNF4α antibody that
recognized ectopic WT HNF4α (Figure 6(c), lane 1) but not
PPARα or RXRα (data not shown). As previously shown
in this study, HNF4α was either physically bound and/or
was part of a complex bound to TB PPRE3 (Figure 6(c),
lane 3). Intriguingly, when PPARα,R X R α and HNF4α
proteins were incubated altogether (Figure 6(c), lane 2),
the signal for HNF4α was stronger supporting the notion
that PPARα/RXRα may favour the binding and/or the
recruitment of HNF4α to TB PPRE3. In contrast to TB
PPRE3 and in support of transactivation assays from others,
competition between PPARα/RXRα and HNF4α for binding
to ACOX-I PPRE was found, validating our experimental
system (Figure 6(c), compare lane 4 and lane 5) [36].
3.8. Physical Interaction between RXRα and HNF4α. The
detection of increased HNF4α p r o t e i no nt h eT BP P R E 3
i nt h ep r e s e n c eo fP P A R α and RXRα may result from
physicalinteractionbetweenPPARα/RXRαandHNF4α.This
hypothesis merits further investigation especially because we
found that DN HNF4α (deﬁcient for DNA binding) was
able to further enhance the PPARα/RXRα transactivation
from TB PPRE3, possibly via protein-protein interactions
(Figure 5(b)). Therefore, the interaction of PPARα,R X R α
or PPARα/RXRα with HNF4α was assessed in solution in
the absence of DNA using coimmunoprecipitation (CoIP)
assays. Nuclear protein extracts from transfected COS-7 cells
(see details, Figure 6(d)) were ﬁrst immunoprecipitated with
a polyclonal PPARα antibody that mapped the N-terminus
partoftheprotein,beforebeinganalyzedbyWesternblotting
with a polyclonal HNF4α antibody (Figure 6(d), lanes 2,
3, 5, and 7). In agreement with the lack of endogenous
HNF4α in COS-7 cells, no signal was observed in absence of
ectopic HNF4α (Figure 6(d), lane 7). Transient transfection
of HNF4α led to the appearance of very faint bands
(Figure 6(d), lanes 2 and 3) possibly indicating a weak inter-
action between PPARα and HNF4α.W h e nP P A R α,R X R α
and HNF4α proteins were present altogether (Figure 6(d),
lane 5), a little signal was still observed suggesting that
PPARα either directly or via a n o t h e rp r o t e i np a r t n e rs u c ha s
RXRα,m a yi n t e r a c tw i t hH N F 4 α. Alternatively, we cannot
exclude the possibility that the interaction between HNF4α
and PPARα/RXRα may partly mask the epitope recognized
by the PPARα antibody.
To go a step further in our study, CoIP assays were also
performed using a polyclonal RXRα (the obligate PPARα
partner) for the immunoprecipitation step. Remarkably,
it was found that RXRα massively interacts with HNF4α
in solution (Figure 6(d), lane 6). It is worth noting that
when the immunoprecipitation step was performed with the
HNF4α antibody and the Western blotting with the RXRα
antibody respectively, we and others failed to observe any
signals[37](datanotshown).Thismightbetheconsequence
of an epitope mapping at the C-terminus of HNF4α,a
region critical for protein-protein interaction. Therefore, the
epitope may be not accessible to the antibody used.
Because the endogenous PPARα expression is barely
detected in COS-7 cells (data not shown) and since the
signal observed in absence of ectopic PPARα was similar
(Figure 6(d), compare lane 4 and 6), it can be concluded
that HNF4αinteracts with RXRαirrespective of the presence
of PPARα. The signals observed in lanes 4 and 6 are in
concordance with the apparent molecular weight obtained
with the ectopic transfected WT HNF4α (Figure 6(d), lane
1).
Overall, our results point towards a physical interaction
in solution between HNF4α and RXRα.
3.9. HNF4α is Involved in the PPARα-Regulated Induction of
Thb in the Liver. In order to check whether our in vitro
ﬁndings are translated in vivo and because a dichotomy may
exist in the function of HNF4α in adult and fetal liver, we
next exploredthe impactof Hnf4αdeletion onbasal and Wy-
induced expression of Thb, Tha, and SCPx/SCP2 thiolase in
adult mice with conditional hepatic disruption of HNF4α
(
￿LH N F 4 α)[ 17]. Our experimental conditions reproduced
the classical pattern of ApoAIV expression associated with
the selective Hnf4α deﬁciency in the liver (Figure 7). When
compared to WT mice, the expression of Thb and Scpx
was signiﬁcantly lower in
￿LH N F 4 α mice (P = .029 and
P<. 0001 for Thb and Scpx, resp.). Tha expression was not
aﬀected by hepatic Hnf4α deletion (P = .179). This piece of
data supports our previous ﬁnding that Tha is not a HNF4α
regulated gene. Furthermore, levels of mRNA for Thb, Tha,
and Scpx were all signiﬁcantly induced by Wy (P = .001,
P<. 0001 and P = .001 for Thb, Tha, and Scpx,r e s p . ) .O f12 PPAR Research
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note, the eﬀect of HNF4α was Wy-sensitive (Wy∗genotype
interaction, I: P = .05) only for Thb. While the expression
of Tha and Scpx tended to be lower in
￿LH N F 4 α mice fed
Wy (P = .372 and .228 for Tha and Scpx,r e s p . ) ,i tw a sn o t
signiﬁcant. Together, our data support the involvement of
HNF4α in the PPARα-regulated induction of Thb in vivo.
4.Discussion
This studycontributestotheunderstandingoftheregulation
of the Thb gene by the nuclear receptors PPARα and HNF4α.
Under basal conditions, hepatic Thb mRNA levels were
not aﬀected by PPARα deletion, similar to other directPPAR Research 13
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Figure 7:The PPARα-regulated induction of Thbis potentiated by HNF4α inthe liver.HepaticmRNAlevels intheliver-speciﬁcally HNF4α-
disrupted (HNF4α
￿L) and HNF4α F/F-fed control or Wy14,643-containing diet (0.1% w/w) for ﬁve days. Total RNA extracted from livers
of these mice were subjected to real-time PCR analysis. The expression signals from the WT mice that did not receive Wy were arbitrarily
set at 1. The results are shown as a relative expression to β-actin mRNA levels as normalizationcontrol. Error bars represent standard error
(SE) and data are expressed as the mean ± S.E. (n = 4 for each condition). Signiﬁcanteﬀects were calculated using two-way ANOVA test for
the genotype (G), Wy14,643 (Wy) and the interaction between both parameters (I). Results are indicated at the top of each ﬁgure. In bold,
parameters that are under the cutoﬀ for statistical signiﬁcance (P value of .05 or below). Wy: Wy14,643.
PPARα target genes such as the G0/G1 switch gene 2 or the
gene encoding the soluble Interleukin-1 Receptor antagonist
[38, 39]. This is not surprising since either a physiological
stimulus such as fasting or a chronic stimulus like high
f a td i e ti sr e q u i r e df o rt h ea c t i v a t i o no fP P A R α-dependent
signalling system in liver [40, 41]. Disruption of PPARα
completely abolished Wy-mediated induction of Thb mRNA
levels. Because the induction of Thb gene expression by
PPARα agonists was robust, we hypothesized the presence
of more than a single functional PPRE within the promoter
and/or Thb gene sequence. In line with this, we previously
reported on the characterization of TB PPRE2 by which
PPARα can transactivate [12]. This followup study now
brings evidence that the molecular regulation of Thb by
PPARα in liver is more complex than previously expected
since it also depends on a novel cis-acting element that
we named TB PPRE3, an atypical PPRE composed of
two sequential DR1 sequences separated by one nucleotide
thereby forming an internal DR1 element.
The presence of more than a single PPRE in close
proximity (so-called PPRE clusters) has been proposed for
the mouse and human version of the Fiaf/Angptl4 and Ucp3
g e n e sa sw e l la sf o rt h em o u s ec a t a l a s ea n dr a tC y p 4 a 1g e n e s
[9, 42, 43]. Four adjacent PPREs are present in intron 3
of the highly PPAR sensitive target Fiaf/Angptl4 but only
a single PPRE is functional [44]. It can be argued that
in contrast to Thb, no overlapping was reported for these
four PPREs rending only speculative a potential comparison14 PPAR Research
between the two situations. While the presence of more
than a single PPRE in a genomic sequence is not unique,
overlapping of PPREs appears to be a rare occurrence. Wen
et al. recently reported that the mouse Octn2 gene contains
three overlapping PPREs in intron 1, yet only a single PPRE
was predominant [34]. Similar to Thb, the presence of three
PPREs in the genomicsequence ofOctn2 is likely responsible
for its massive transcriptional response to activated PPARα.
With respect to other peroxisomal genes, the SCPx/SCP2
thiolase gene was previously identiﬁed as a target of PPARα
with two separated DR1 PPRE motifs localized in the
promoter region [45]. It is also worth noting that Mfp1
displays a PPRE composed of four consensus hexameric
TGACCT half-sites in an arrangement of two DR1 elements
separated by two base pairs, thereby also forming an internal
DR2 element [28, 29]. Similar to Mfp1, Thb appears to
be the second peroxisomal oxidative gene that displays this
particular feature.
AlthoughthepresenceofmultiplePPREsmayberespon-
sible for the large responsiveness of Thb mRNA levels to
activated PPARα, alternative explanations are also consid-
ered. In this respect, previous data have shown that Thb
mRNA was positively regulated by the liver X receptor alpha
[46]. Given that transcription of the liver X receptor alpha
gene has been proposed to be dependent on PPARα,i tc a n
be concluded that the PPARα signalling pathway modulates
liver Thb expression through distinct but complementary
mechanisms [47].
Furthermore, ﬂanking the internal DR1 element of
TB PPRE3 are two half-sites that have been shown to
enhance and stabilize the formation of dimeric complexes
made by type II nuclear receptors such as RXR and the
thyroid hormone receptor [48]. Therefore, one can make the
attractive hypothesis that such a mechanism also takes place
as far as the PPAR/RXR heterodimer is concerned. It could
then partly support the large response of the reporter vector
to PPARα agonists in transactivation assays. Moreover, using
electrophoretic mobility shift assays, others have previously
classiﬁed the binding eﬃciency of PPARα to MFP-1 PPRE
as high and transactivation assays further supported the
functional relevance of this classiﬁcation [49]. Given that the
structure of TB PPRE3 is close to that of the MFP-1 PPRE,
the presence of the TB PPRE3 in the genomic DNAsequence
of Thb may be enough to explain the large responsiveness of
Thb mRNA levels to PPARα agonists.
In addition to PPARα, the nuclear receptor HNF4α
is abundantly expressed in liver and shares with PPARα
some similar DNA-binding properties [50]. Because several
DR1 motifs (potential candidates for HNF4α binding)
have been identiﬁed in the sequence of Thb,r e g u l a t i o n
of Thb by HNF4α was studied using RNA from HNF4α
null embryos and HNF4
￿L adult mice. It was found
that hepatic Thb mRNA levels were dependent on HNF4α
because it was either completely absent (embryo) or strongly
reduced (adult) in liver upon HNF4α ablation. Yet, HNF4α
transactivations from TB PPRE3 or DR1int5 were rather
disappointing. At this point of investigation, our data of
transactivation assays about HNF4α and TB PPRE3 or
DR1int5 are at odds with the clear cut picture of Thb gene
expression in the liver of HNF4α-deﬁcient embryos/mice.
A plausible explanation is that another critical HNF4α-
response elementsmightbelocatedelsewhereinthegenomic
DNA.Theoretically, it is also possible that takenindividually,
the DR1s tested are poor HNF4α-response elements while
together in the genomic context of the Thb gene sequence,
these distal elements simultaneously act to trigger a massive
transcriptional response. Alternatively, we cannot rule out
that a critical response element for HNF4αis located very far
from the initiation start site of Thb in another part of the
chromosome that would bend to speciﬁcally interact with
the genomic sequence of Thb. Such a regulation has been
recently describedfor theregulation ofUcp2 and Ucp3 by the
nuclear receptor PPARγ [51].
Moreover, it is diﬃcult to estimate to what extent PPARα
might be involved in the lack of Thb observed in vivo in
HNF4
￿Lmice.Diﬀerentstudieshaveprovidedevidencethat
thesteady-state levelsofPPARαmRNAwere decreasedin the
liver ofHNF4
￿L adult mice [17, 52]. Ongoing investigations
by DNA ChIP also showed that the PPARα promoter was
physically bound by HNF4α classifying PPARα as a novel
and direct target of HNF4α [52]. Interestingly, binding of
PPARα to the HNF4α promoter/enhancer was also reported
[52]. Therefore, the authors concluded the existence of
combinatorial regulation of the expression of Pparα and
HNF4α,acting inacoordinatedfashion ontheirdownstream
targets genes. Because basal Thb mRNA levels in the liver
of PPARα null and WT mice was similar under regular
conditions, a critical role for PPARα in Thb regulation is
unlikely in HNF4
￿Lm i c e .
Besides its classiﬁcation as a strong constitutive tran-
scriptional activator, it was previously demonstrated that
HNF4α can form a stable aﬃnity complex with other
transcription factors such as SHP, SREBP-1c, SREBP-2,
and HNF1α leading to the modulation of the expression
of some of their respective target genes [53, 54]. These
data raise an important conceptual question about the
comparison between HNF4α as a conventional nuclear
receptor/transcription factor and coactivator. Our data are
consistent with the explanation that HNF4α interacts with
RXRα in solution (Figure 6(d)) and in the presence of DNA
(Figure 6(c)) without disrupting the binding of the liganded
PPARα/RXRα heterodimer (Figure 6(b)).
While further studies are necessary to determine the
stoichiometry of this interaction, it is worth underlining that
HNF4α potentiated the transactivation from TB PPRE3 by
liganded PPARα/RXRα in four diﬀerent cell lines ruling out
the hypothesisofanartefact duetotheuse ofaparticular cell
line. Our data are reminiscent of those obtained by Winrow
et al. who previously reported on the functional cooperation
between PPARα and HNF4α in the induction of Luc
activity from the MFP-1 PPRE [36]. As previously reported
by others, HNF4α decreased transcriptional activation of
ACOX-I PPRE by PPARα/RXRα [36, 55]. Importantly, our
c u r r e n tﬁ n d i n gt h a tH N F 4 α is involved in the PPARα-
induced expression of Thb in liver in mice indicates that our
data of transactivation assays observed in COS-7 cells are
translated in vivo.PPAR Research 15
Thelingeringquestionarises why HNF4αwouldenhance
transactivation from TB PPRE3 and MFP-1 PPRE while
decrease that from ACOX-I PPRE? The molecular mech-
anism by which HNF4α inﬂuences transactivation by
PPARα/RXRα from TB PPRE3 likely involves interaction
betweenHNF4αandRXRα.Furthermore,thespeciﬁcassoci-
ation of coactivators/corepressors with PPARα/RXRα or the
conﬁguration of the chromatin might strengthen or weaken
the stability of PPARα/RXRα to the diﬀerent PPREs render-
ingthemmoreorlesssusceptibletointeraction withHNF4α.
It is, therefore, expected that the enhanced PPARα/RXRα-
mediated transactivation by HNF4α only concerns a very
limited subset of PPARα target genes that display composite
PPREs, similar to those identiﬁed in Thb and Mfp-1.
Lastly, the chromatin structure within theserine protease
inhibitor (serpin) gene cluster was found to be orches-
trated by the nuclear receptor HNF4α and HNF1α [56].
Additionally, expression of the chromatin remodeling genes
Smarcd3 and Cdt-1 was found to be altered in HNF4
￿L
mice suggesting that these factors are potential candidates
that may contribute to the indirect eﬀects of HNF4α [57].
In support of this idea, it can be hypothesized that a
similar regulation also takes place at the Thb gene locus.
Supportingthishypothesis,wefoundthatthetransactivation
of PPARα/RXRα via TB PPRE3 was similarly induced by
HNF4α or trichostatin A, a well-known inhibitor of histone
deacetylation (data not shown).
From a physiological point of view, recent work has
shed light on the critical role of HNF4α in the control
of the expression of enzymes that drive fatty acid β-
oxidation for energy production in Drosophila [58]. Given
that PPARα also acts at the level of the β-oxidation pathway
in mammals, it may come as no big surprise that the PPARα
and HNF4α signaling routes intersect [31]. To what degree
the interaction between the PPARα/RXRα heterodimer and
HNF4α inﬂuence peroxisomal lipid catabolism under more
physiological conditions deserves further investigation.
In summary, this study shows that Thb is a dual target of
the two liver enriched nuclear receptors HNF4α and PPARα.
Our work also indicates that PPARα/RXRα likely contacts
HNF4α via RXRα and in turn modulates the transcription
of Thb. Hence, through interaction with other previously
bound nuclear receptors to chromatin DNA, HNF4α likely
facilitates the recruitment of coactivators and may enhance
gene transcription.The convergence of the HNF4α,P P A R α,
and RXRα signalling pathways underscores the complex
interplay involved for the correct transcriptional response of
peroxisomal β-oxidation.
Abbreviations
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